S&P Futures
4,272.00 -9.00 (-0.21%) Dow Futures
33,654.00 -64.00 (-0.19%) Nasdaq Futures
13,547.50 -30.25 (-0.22%) Russell 2000 Futures
2,011.70 -5.20 (-0.26%) Crude Oil
91.88 -0.21 (-0.23%) Gold
1,815.30 -0.20 (-0.01%)
Bio-Path Holdings, Inc. (BPTH)
After hours:
Chart Events
Performance Outlook
| Previous Close | 4.0900 |
| Open | 4.1100 |
| Bid | 4.1600 x 800 |
| Ask | 4.2400 x 1200 |
| Day's Range | 4.0600 - 4.2400 |
| 52 Week Range | 2.6800 - 8.6200 |
| Volume | |
| Avg. Volume | 35,227 |
| Market Cap | 29.786M |
| Beta (5Y Monthly) | 1.48 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.6020 |
| Earnings Date | Aug 16, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for BPTH
Related Research
- Bio-Path Holdings, Inc.Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total revenue is generated in the United States.RatingFair ValueEconomic Moat7 days agoMorningstar
- GlobeNewswire
Bio-Path Holdings to Announce Second Quarter 2022 Financial Results on August 16, 2022
HOUSTON, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Tuesday, August 16, 2022 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2022 and to provide a business overview. To access the live conferenc
- ACCESSWIRE
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (Nasdaq:BPTH)
DALLAS, TX / ACCESSWIRE / June 13, 2022 / Bio-Path Holdings, Inc. (Nasdaq:BPTH) The full report can be accessed by clicking on the following link: http://stonegateinc.
- GlobeNewswire
Bio-Path Holdings Reports First Quarter 2022 Financial Results
Conference Call to be Held Today at 8:30 A.M. ETHOUSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the first quarter ended March 31, 2022 and provided an update on recent corporate developments. “Throughout the first quarter, we continued to advance our missi
